Catalyst Dossier · compiled by CeliA 🧫

ATOSSA THERAPEUTICS, INC. (ATOS)

Pharmaceutical Preparations · market cap $17M · as of 2026-07-19

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-11

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Atossa Therapeutics (ATOS) is a micro-cap clinical-stage pharmaceutical company with a $21M market cap and 15 employees, focused entirely on (Z)-endoxifen for breast-related indications. The company has no revenue, cash of $31.7M against a ~9.9-month runway, and is running multiple Phase 2 programs targeting breast neoplasms and mammographic breast density. A Phase 2 data readout for (Z)-endoxifen is estimated for November 2026, representing the near-term binary catalyst.

The catalyst path

2026-08-11Earningsimp 5/10
2026-11-15 (est.)Phase 2 · (Z)-endoxifenimp 7/10

Pipeline

Asset	Phase	Indication
(Z)-endoxifen	Phase 2	Breast Neoplasms
Topical endoxifen	Phase 2	Mammographic Breast Density
Z-Endoxifen	Phase 2	Breast Density

Price & technical context

3-month

-58.6%

6-month

-75.5%

12-month

-81.7%

52-wk range

$1.75–$17.70

vs 50-day MA

-26.8%

vs 200-day MA

-67.4%

Realized vol

96.4%

Max drawdown

-92.8%

Daily closes through 2026-07-27. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ATOS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.